Torrent Pharmaceuticals logo

Torrent Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap

Torrent Pharmaceuticals Limited · Face value ₹5 · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,580.00up ₹23.00 (0.50%)BSE ₹4,564.10

Share price at the NSE close on 29 Oct 2026. Previous close ₹4,557.00.

29 Oct: open ₹4,540.00, high ₹4,610.90, low ₹4,525.30

52-week range of traded prices to 29 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
Market cap
₹1,74,208 Cr61st largest listed
P/E
82.02
P/B
9.48
Dividend yield
0.83%
ROE
15.8%
ROCE
12.0%
Debt to equity
0.76
Volume, NSE
3,20,05563.1% delivered

Torrent Pharmaceuticals' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

10 years at a glance

₹ crore, years to March.Torrent Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
5,857934Mar 176,002678Mar 187,6734364,847Mar 197,9391,0254,395Mar 208,0051,2523,645Mar 218,5087774,018Mar 229,6201,2455,297Mar 2310,7281,6563,938Mar 2411,5161,9113,026Mar 2513,9802,13814,798Mar 26
Peak revenue ₹13,980 Cr, year to Mar 2026; lowest ₹5,857 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
32.6%5.7%23.5%22.5%25.9%27.3%31.0%28.6%29.5%31.4%32.3%32.6%15.9%11.3%5.7%12.9%15.6%9.1%12.9%15.4%16.6%15.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.4% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue13,980
  2. Materials and goods−3,388
  3. Employee costs−2,671
  4. Other expenses−3,362
  5. Operating profit4,559
  6. Depreciation−1,119
  7. Other income−94
  8. One-off items−89
  9. Finance costs−385
  10. Profit before tax2,872
  11. Tax−734
  12. Net profit2,138

What the company owns

  • Plant, investments and other assets₹36,112 Cr
  • Inventory₹3,138 Cr
  • Receivables₹3,031 Cr
  • Cash and bank₹1,165 Cr
  • Current investments₹866 Cr

What pays for it: net worth and liabilities

  • Net worth₹17,585 Cr
  • Borrowings₹14,798 Cr
  • Other liabilities₹9,571 Cr
  • Owed to suppliers₹2,358 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Torrent Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026Twelve monthsFiled 23 Oct
Revenue from operations5,8576,0027,6737,9398,0058,5089,62010,72811,51613,98017,400
4,4794,6535,6895,7695,5206,0776,7787,3607,7959,42111,626
Materials and goods bought1,7911,6742,2192,1672,1472,4432,7352,6862,7763,3884,201
Employee costs9931,1351,4041,4291,4401,5261,6781,9842,2032,6713,227
Other expenses1,6951,8442,0662,1731,9332,1082,3652,6902,8163,3624,198
Operating profit before depreciation1,3781,3491,9842,1702,4852,4312,8423,3683,7214,5595,774
Operating margin23.5%22.5%25.9%27.3%31.0%28.6%29.5%31.4%32.3%32.6%33.2%
Materials, % of revenue30.6%27.9%28.9%27.3%26.8%28.7%28.4%25.0%24.1%24.2%24.1%
Employee costs, % of revenue17.0%18.9%18.3%18.0%18.0%17.9%17.4%18.5%19.1%19.1%18.5%
Other expenses, % of revenue28.9%30.7%26.9%27.4%24.1%24.8%24.6%25.1%24.5%24.0%24.1%
Depreciation and amortisation3074096186546586627078087951,1191,916
Operating profit after depreciation1,0719401,3661,5161,8271,7692,1352,5602,9263,4403,858
Other income2232995712257197455823−94−52
Finance costs206308504451358255333354252385886
Profit before one-off items and tax1,0889319191,1871,5261,7111,8472,2642,6972,9612,920
One-off items00−35700−485088−24−89−107
Profit before tax1,0889315621,1871,5261,2261,8472,3522,6732,8722,813
154253126162274449602696762734714
9346784361,0251,2527771,2451,6561,9112,1382,099
Other comprehensive income––33−19210012−13717−93−180−33
Total comprehensive income––4698331,3527891,1081,6731,8181,9582,066
Net margin15.9%11.3%5.7%12.9%15.6%9.1%12.9%15.4%16.6%15.3%12.1%

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026Half yearFiled 23 Oct
4,7244,8245,8385,9536,1986,8567,59117,58518,373
4,7244,8245,8385,9536,1986,8567,5918,38918,373
Share capital85858585169169169169190
Reserves4,6394,7395,7535,8686,0296,6877,4228,22018,183
Belonging to outside owners of subsidiaries00000–09,1960
4,8474,3953,6454,0185,2973,9383,02614,79813,874
5,1665,4824,8914,4155,4475,4264,7178,3437,984
4,2313,7323,3462,7323,3672,7792,68218,38418,258
14,12114,03814,07513,10015,01215,06114,99044,31244,615
9,0839,0298,5517,8059,6839,4509,36734,91934,097
5,0385,0075,5225,1655,3145,6115,6239,39210,517
Net debt3,6803,7292,9023,4314,5702,9582,33512,76710,888
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026Half year
2,0111,8032,3683,2662,5853,0232,452
2,1872,2242,7663,7643,1883,8322,586
−337−353−18418−481−342−621
Receivables65−113−2907817−254−453
Inventories−532219256−49−26235−43
Payables130−459−58414−278164−134
Other working capital0074−2542−2879
Tax paid−176−421−398−498−603−809−134
Capital spending335203574433611677389
Free cash flow1,6761,6001,7942,8331,9742,3462,063
−449−198−2,356−168−540−12,713−1,183
−1,656−1,78177−2,779−2,29810,151−1,505
Dividends paid3386778631,0151,0831,289381
Shares bought back0000000
Shares issued0000000
Net change in cash−94−17689319−253461−236
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Torrent Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
₹27.59₹20.04₹12.89₹30.28₹36.99₹22.97₹36.79₹48.94₹56.47₹63.92
As stated that year₹55.17₹40.07₹25.78₹60.55₹73.98₹45.93₹36.79₹48.94₹56.47₹63.92
₹27.59₹20.04₹12.89₹30.28₹36.99–₹36.79₹48.94₹56.47₹63.92
₹7.00₹7.00₹8.50₹16.00₹17.50₹12.50₹22.00₹28.00₹32.00₹38.00
––₹139.57₹142.52₹172.48₹175.87₹183.12₹202.56₹224.28₹247.86
Dividend payout25.4%34.9%66.0%52.8%47.3%54.5%59.8%57.2%56.7%59.5%
Shareholder yield––––0.8%1.4%1.7%1.2%1.0%0.9%
Market cap at the year end (₹ crore)26,27421,14932,99433,36743,06847,24652,02488,0161,09,2481,42,831
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Torrent Pharmaceuticals PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue growth−12.3%2.5%27.8%3.5%0.8%6.3%13.1%11.5%7.3%21.4%
Operating profit growth−49.3%−2.1%47.1%9.4%14.5%−2.2%16.9%18.5%10.5%22.5%
Net profit growth−45.8%−27.4%−35.7%135.1%22.1%−37.9%60.2%33.0%15.4%11.9%
Earnings per share growth–−27.4%−35.7%134.9%22.2%−37.9%60.2%33.0%15.4%13.2%
––9.2%21.5%23.5%13.2%20.5%25.4%26.5%27.1%
–––12.2 pts2.0 pts−10.3 pts7.3 pts4.9 pts1.1 pts0.6 pts
From the net margin–––11.7 pts4.5 pts−9.8 pts5.5 pts3.9 pts1.9 pts−1.8 pts
From asset turnover–––0.8 pts0.3 pts1.4 pts1.7 pts1.0 pts2.0 pts−9.5 pts
From borrowing–––−0.3 pts−2.8 pts−1.9 pts0.1 pts−0.1 pts−2.8 pts11.9 pts
Return on capital employed––14.3%16.4%19.3%17.7%18.6%23.7%27.6%10.6%
Cash conversion––––160.6%232.0%190.2%197.2%135.3%141.4%
Interest cover5.23.12.73.45.16.96.47.211.68.9
Debt to equity––1.030.910.620.680.850.570.400.84
Receivable days––6876697074635979
Inventory days––318362456368298310334338
Payable days––345350351250224284239254
Cash conversion cycle, days––418817418814789154163
Working capital days––−17−2278874526557
Asset turnover––0.540.560.570.630.680.710.770.47
Assets per rupee of net worth––2.992.952.642.302.312.302.083.71
Sales per rupee of plant––2.742.692.783.153.473.253.332.85
Capital spending to depreciation––––0.510.310.810.540.770.61
Plant being built, % of plant in use––17.1%19.5%25.8%20.1%24.8%8.5%10.6%9.3%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
7.3%
Cash from operations against operating profit
66.3%
Measure10 years5 years3 years
Revenue growth, yearly rate7.7%11.8%13.3%
Profit growth, yearly rate2.3%11.6%20.2%
Return on equity, average–22.5%26.3%
Return on capital employed, average–19.6%20.6%
Operating margin, average28.5%30.9%32.1%
Net margin, average13.1%13.9%15.8%
Asset turnover, average–0.650.65
Cash conversion cycle, days, average–148135
Interest cover, average6.18.29.3
Debt to equity, average–0.670.60

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations13,0458,8743,023
Cash from investing−15,975−13,421−12,713
Cash from financing3,3705,07410,151
Capital spending2,4981,721677
Dividends paid4,9273,3871,289
Shares bought back000
Shares issued for cash000
Borrowings raised15,05012,59412,594
Borrowings repaid4,9722,967672

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––976896
Altman Z-scorePublished threshold 1.81––3.353.564.775.695.218.3811.044.05
Beneish M-scorePublished threshold −1.78––––−2.78−2.80−2.64−3.04−2.64−1.78
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−2.21−6.098.77−9.59−0.8939.89
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.892.021.711.56
Receivables growth less revenue growthOur threshold 0 percentage points–––11.37−8.470.945.97−16.66−6.1040.95
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––13.3525.74−21.96−21.383.998.151.45
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.550.40−1.08−0.720.880.124.78
Assets under construction, years of additionsOur threshold 2 years of additions–––0.721.261.130.890.210.390.18
Effective tax ratePublished threshold 17.16 per cent14.1527.1822.4213.6517.9636.6232.5929.5928.5125.56
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––2.2811.048.425.95−2.61
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
7 Oct 2026India Ratings and Research Private LimitedBank loan facilitiesIND AA+Review, OtherPositive2,350
7 Oct 2026India Ratings and Research Private LimitedIssuer RatingIND AA+Review, OtherPositive
7 Oct 2026India Ratings and Research Private LimitedCommercial paperIND A1+New, New700
7 Oct 2026India Ratings and Research Private LimitedNon-convertible debenturesIND AA+Review, OtherPositive410
21 Jul 2026ICRA LimitedCommercial Paper[ICRA]A1+Review, Other1,500
21 Jul 2026ICRA LimitedFund-based/Non-fund based-Others[ICRA]AA+Review, OtherStable379
21 Jul 2026ICRA LimitedUnallocated limits-Unallocated limits[ICRA]AA+Review, OtherStable271
21 Jul 2026ICRA LimitedFund-based-Cash credit[ICRA]AA+Review, OtherStable2,745
21 Jul 2026ICRA LimitedNon Convertible Debentures[ICRA]AA+Review, OtherStable2,490
30 Sep 2025ICRA LimitedFund Based-Term Loan[ICRA]AA+Review, Re-affirmStable57.14
30 Sep 2025ICRA LimitedUnallocated-Unallocated[ICRA]AA+Review, Re-affirmStable592.86
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.